TY - JOUR
T1 - Brain Cancers in Genetic Syndromes
AU - Komlodi-Pasztor, Edina
AU - Blakeley, Jaishri O.
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/11
Y1 - 2021/11
N2 - Purpose of Review: Although genetic conditions that cause primary central nervous system tumors are rare, their pathophysiology influences both treatment and surveillance. This article reviews the most frequently occurring genetic conditions associated with brain cancers and highlights the most recent therapeutic approaches in the treatment of Lynch syndrome (and other disorders of the mismatch repair system), neurofibromatosis 1, and Li–Fraumeni syndrome. Recent Findings: Recent advances in molecular diagnostics have considerably improved the ability to diagnose genetic conditions in people with primary brain tumors. The common application of next-generation sequencing analyses of tissue increases the frequency with which clinicians are forced to address the possibility of an underlying genetic condition based on tissue molecular findings. Summary: Clinicians must be aware of the clinical presentation of genetic conditions predisposing to brain tumors in order to discern which patients are appropriate for germline genetic testing. Advances in therapeutics for specific genetic variants are increasingly available, and accurately diagnosing an underlying genetic condition may directly impact patient outcomes.
AB - Purpose of Review: Although genetic conditions that cause primary central nervous system tumors are rare, their pathophysiology influences both treatment and surveillance. This article reviews the most frequently occurring genetic conditions associated with brain cancers and highlights the most recent therapeutic approaches in the treatment of Lynch syndrome (and other disorders of the mismatch repair system), neurofibromatosis 1, and Li–Fraumeni syndrome. Recent Findings: Recent advances in molecular diagnostics have considerably improved the ability to diagnose genetic conditions in people with primary brain tumors. The common application of next-generation sequencing analyses of tissue increases the frequency with which clinicians are forced to address the possibility of an underlying genetic condition based on tissue molecular findings. Summary: Clinicians must be aware of the clinical presentation of genetic conditions predisposing to brain tumors in order to discern which patients are appropriate for germline genetic testing. Advances in therapeutics for specific genetic variants are increasingly available, and accurately diagnosing an underlying genetic condition may directly impact patient outcomes.
KW - Brain cancer
KW - Genetic syndromes
KW - Li–Fraumeni syndrome
KW - Lynch syndrome
KW - Mismatch repair system
KW - Neurofibromatosis 1
UR - http://www.scopus.com/inward/record.url?scp=85119616309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119616309&partnerID=8YFLogxK
U2 - 10.1007/s11910-021-01149-4
DO - 10.1007/s11910-021-01149-4
M3 - Review article
C2 - 34806136
AN - SCOPUS:85119616309
SN - 1528-4042
VL - 21
JO - Current neurology and neuroscience reports
JF - Current neurology and neuroscience reports
IS - 11
M1 - 64
ER -